Fresenius Medical Care AG (FRA:FME)
Germany · Delayed Price · Currency is EUR 38.01
+0.58 (1.55%)
At close: Jan 30, 2026
Fresenius Medical Care AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 19,643 | 19,336 | 19,454 | 19,398 | 17,619 | 17,859 | |
Revenue Growth (YoY) | 2.10% | -0.60% | 0.29% | 10.10% | -1.35% | 2.19% |
Cost of Revenue | 14,732 | 14,579 | 14,529 | 14,504 | 12,846 | 12,322 |
Gross Profit | 4,911 | 4,757 | 4,925 | 4,894 | 4,773 | 5,537 |
Selling, General & Admin | 3,088 | 3,143 | 3,196 | 3,170 | 2,773 | 2,966 |
Research & Development | 169.41 | 183.49 | 231.97 | 228.62 | 220.78 | 193.77 |
Other Operating Expenses | -32.5 | -109.03 | -26.86 | -43.25 | -124.41 | - |
Operating Expenses | 3,225 | 3,217 | 3,401 | 3,356 | 2,869 | 3,160 |
Operating Income | 1,686 | 1,539 | 1,524 | 1,538 | 1,904 | 2,378 |
Interest Expense | -386.41 | -407.04 | -424.64 | -360.14 | -353.6 | -409.98 |
Interest & Investment Income | 77.22 | 71.58 | 88.22 | 67.66 | 73.17 | 41.96 |
Earnings From Equity Investments | 171.83 | 134.88 | 121.79 | 66.56 | 92.18 | 94.52 |
Currency Exchange Gain (Loss) | -31.84 | -23.06 | -35.5 | -36.83 | -9.9 | - |
EBT Excluding Unusual Items | 1,517 | 1,316 | 1,273 | 1,275 | 1,706 | 2,104 |
Merger & Restructuring Charges | -238.47 | -317.48 | -259.92 | -147.95 | -37.55 | - |
Impairment of Goodwill | - | - | - | - | - | -193.98 |
Gain (Loss) on Sale of Investments | -98.01 | 44.03 | 14.67 | 44.85 | -87.63 | - |
Gain (Loss) on Sale of Assets | 2.16 | 14.66 | 4.84 | 47.17 | -8.63 | - |
Asset Writedown | - | - | - | - | - | -3.25 |
Other Unusual Items | - | - | - | - | - | 29.41 |
Pretax Income | 1,183 | 1,057 | 1,033 | 1,219 | 1,572 | 1,936 |
Income Tax Expense | 275.53 | 316.06 | 300.56 | 324.95 | 352.83 | 500.56 |
Earnings From Continuing Operations | 907.37 | 740.87 | 732.46 | 894.33 | 1,219 | 1,436 |
Minority Interest in Earnings | -189.18 | -202.96 | -233.46 | -220.92 | -249.72 | -271.46 |
Net Income | 718.19 | 537.91 | 499 | 673.41 | 969.31 | 1,164 |
Net Income to Common | 718.19 | 537.91 | 499 | 673.41 | 969.31 | 1,164 |
Net Income Growth | 8.99% | 7.80% | -25.90% | -30.53% | -16.75% | -2.94% |
Shares Outstanding (Basic) | 293 | 293 | 293 | 293 | 293 | 294 |
Shares Outstanding (Diluted) | 293 | 293 | 293 | 293 | 293 | 294 |
Shares Change (YoY) | -0.11% | - | 0.06% | 0.06% | -0.41% | -2.80% |
EPS (Basic) | 2.45 | 1.83 | 1.70 | 2.30 | 3.31 | 3.96 |
EPS (Diluted) | 2.44 | 1.83 | 1.70 | 2.30 | 3.31 | 3.96 |
EPS Growth | 8.62% | 7.65% | -25.97% | -30.60% | -16.44% | -0.01% |
Free Cash Flow | 1,778 | 1,687 | 1,944 | 1,443 | 1,635 | 3,181 |
Free Cash Flow Per Share | 6.07 | 5.75 | 6.63 | 4.92 | 5.58 | 10.81 |
Dividend Per Share | 1.440 | 1.440 | 1.190 | 1.120 | 1.350 | 1.340 |
Dividend Growth | 21.01% | 21.01% | 6.25% | -17.04% | 0.75% | 11.67% |
Gross Margin | 25.00% | 24.60% | 25.32% | 25.23% | 27.09% | 31.01% |
Operating Margin | 8.58% | 7.96% | 7.83% | 7.93% | 10.81% | 13.31% |
Profit Margin | 3.66% | 2.78% | 2.56% | 3.47% | 5.50% | 6.52% |
Free Cash Flow Margin | 9.05% | 8.72% | 9.99% | 7.44% | 9.28% | 17.81% |
EBITDA | 2,453 | 2,347 | 2,379 | 2,512 | 2,799 | 3,261 |
EBITDA Margin | 12.49% | 12.14% | 12.23% | 12.95% | 15.88% | 18.26% |
D&A For EBITDA | 766.2 | 807.31 | 855.58 | 973.66 | 894.89 | 882.87 |
EBIT | 1,686 | 1,539 | 1,524 | 1,538 | 1,904 | 2,378 |
EBIT Margin | 8.58% | 7.96% | 7.83% | 7.93% | 10.81% | 13.31% |
Effective Tax Rate | 23.29% | 29.90% | 29.09% | 26.65% | 22.45% | 25.85% |
Revenue as Reported | 19,643 | 19,336 | 19,454 | 19,398 | 17,619 | 17,859 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.